GSK plc
$163.77B- Market cap
- $107.65B
- Debt
- +$44.87B
- Cash
- −$3.40B
Capital structure 71% equity / 29% debt · EV / Revenue 3.70x · EV / EBITDA 19.24x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $107.65B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: GSK stock price at discount vs CDE $49.89 current versus $85.37 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CDE's multiple
Implied fair value · at GSK's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Value edge
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: GSK FY 2025 (ended Dec 31, 2025) · CDE FY 2025 (ended Dec 31, 2025).
Trendline
Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 71% equity / 29% debt · EV / Revenue 3.70x · EV / EBITDA 19.24x
Capital structure 100% equity / 0% debt · EV / Revenue 10.29x · EV / EBITDA 29.72x
GSK carries the larger enterprise value at $163.77B against $21.30B; GSK trades on the lower EV / Revenue multiple (3.70x vs 10.29x); GSK on the lower EV / EBITDA (19.24x vs 29.72x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
GSK plc · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
COEUR MINING, INC. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
—
0.01x
Net debt / EBITDA
Leverage against operating earnings
6.59x
-0.75x
Cash and equivalents
Liquid reserves on the balance sheet
$3.40B
$553.60M
Total debt
Interest-bearing obligations outstanding
$44.87B
$17.00M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PFIZER INC
GSK vs PFE
ELI LILLY & Co
GSK vs LLY
BRISTOL MYERS SQUIBB CO
GSK vs BMY
JOHNSON & JOHNSON
GSK vs JNJ
AbbVie Inc.
GSK vs ABBV
AMGEN INC
GSK vs AMGN
NEWMONT Corp /DE/
GSK vs NEM
BARRICK GOLD CORP
GSK vs GOLD
AGNICO EAGLE MINES LTD
GSK vs AEM
HECLA MINING CO/DE/
GSK vs HL
ROYAL GOLD INC
GSK vs RGLD
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.